IL17A and psoriasis 14, pustular: Phase 3 studies in Japanese patients showed the efficacy of target biological therapies targeting IL-17 and IL-23 (namely, ixeziumab, secukinumab, brodalumab, guselkumab, and risankizumab) in GPP [39,40,41,42,43,44].